[HTML][HTML] Hyaluronic acid association with bacterial, fungal and viral infections: Can hyaluronic acid be used as an antimicrobial polymer for biomedical and …

F Zamboni, CK Wong, MN Collins - Bioactive Materials, 2023 - Elsevier
The relationships between hyaluronic acid (HA) and pathological microorganisms incite new
understandings on microbial infection, tissue penetration, disease progression and lastly …

Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs

EI Nielsen, LE Friberg - Pharmacological reviews, 2013 - ASPET
Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an
important tool for rational drug development and drug use, where developed models …

Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling?

EF Barreto, AJ Webb, GM Pais, AD Rule… - Critical care …, 2021 - journals.lww.com
OBJECTIVES: Beta-lactam antibiotics exhibit high interindividual variability in drug
concentrations in patients with critical illness which led to an interest in the use of …

Acinetobacter baumannii: Envelope Determinants That Control Drug Resistance, Virulence, and Surface Variability

E Geisinger, W Huo, J Hernandez-Bird… - Annual review of …, 2019 - annualreviews.org
Acinetobacter baumannii has emerged as an important nosocomial pathogen, particularly
for patients in intensive care units and with invasive indwelling devices. The most recent …

Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

M Zhao, AJ Lepak, DR Andes - Bioorganic & medicinal chemistry, 2016 - Elsevier
Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of
antimicrobial therapy serve an important role in preclinical assessments of new antibiotics …

Modeling the synergistic elimination of bacteria by phage and the innate immune system

CYJ Leung, JS Weitz - Journal of theoretical biology, 2017 - Elsevier
Phage therapy has been viewed as a potential treatment for bacterial infections for over a
century. Yet, the year 2016 marks one of the first phase I/II human trials of a phage …

The current status and future perspectives of beta-lactam therapeutic drug monitoring in critically Ill patients

E Novy, H Martinière, C Roger - Antibiotics, 2023 - mdpi.com
Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill
patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to …

Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis

E Novy, C Roger, JA Roberts, MO Cotta - Critical Care, 2023 - Springer
Intra-abdominal candidiasis (IAC) is one of the most common of invasive candidiasis
observed in critically ill patients. It is associated with high mortality, with up to 50% of deaths …

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection

MW Sadiq, EI Nielsen, D Khachman, JM Conil… - … of pharmacokinetics and …, 2017 - Springer
The purpose of this study was to develop a whole-body physiologically based
pharmacokinetic (WB-PBPK) model for ciprofloxacin for ICU patients, based on only plasma …

Human neutrophils phagocytose and kill Acinetobacter baumannii and A. pittii

M Lázaro-Díez, I Chapartegui-González… - Scientific reports, 2017 - nature.com
Acinetobacter baumannii is a common cause of health care associated infections worldwide.
A. pittii is an opportunistic pathogen also frequently isolated from Acinetobacter infections …